Galectin Therapeutics Inc. Banner Image

Galectin Therapeutics Inc.

  • Ticker GALT
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Galectin Therapeutics Inc. Logo Image
  • 1-10 Employees
  • Based in Norcross, Georgia
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin (formerly known as GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designationMore by the U.S. Food and Drug Administration. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of combination immunotherapy for advanced melanoma and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development.
4.8 / 5.0 (92)

Galectin Therapeutics Inc. reports have an aggregate usefulness score of 4.8 based on 92 reviews.

Galectin Therapeutics Inc.

Most Recent Annual Report

Galectin Therapeutics Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Galectin Therapeutics Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!